Identification and verification of human biomarkers for early detection of NASH and fibrosis.
Development of a blood-based biomarker panel for detection of NASH-induced fibrosis.
Diagnostics, Human R&D
Health Holland – Grant ID V201700972
1 June 2017 to 31 December 2020
Together with the prevalence of obesity, the risk for developing non-alcoholic steatohepatitis (NASH) is increasing in western population. NASH is characterized by hepatocellular damage and inflammation, which drive the development of fibrosis. Liver fibrosis is strongly associated with long-term overall mortality. Clinical symptoms of liver fibrosis become manifested at an advanced stage of disease and early diagnosis is not possible. Therefore, there is a need for novel biomarkers that can determine the early onset of liver fibrosis. The purpose of this project is to develop a blood-based biomarker panel for the detection of NASH induced fibrosis. The projects builds upon previous (pre-clinical) work which defined a set of candidate biomarker set in mice. The NASH Fibrosis consortium sets out to verify this set of candidates in human and translate this the results into a diagnostic tool for stratification of NASH patients. GenomeScan coordinates the RNA sequencing efforts and provides a BioIT expertise to optimize the analysis of selected genomic markers.
T.b.a. (ongoing project)
This collaboration project is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to TNO to stimulate public-private partnerships.